SCHEMBL24599261

SCHEMBL24599261

FC(F)c1nnc(-c2ccc(Cn3cc(-c4cccs4)nn3)cc2)o1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HDAC6 Q9UBN7 9/20 0.53
▸ CDC7 O00311 1/20 0.45
▸ SPHK2 Q9NRA0 1/20 0.44
▸ SRC P12931 1/20 0.41
▸ RAB9A P51151 4/20 0.40
▸ SMN1; SMN2 Q16637 3/20 0.40
▸ NPC1 O15118 3/20 0.40
▸ KDM4E B2RXH2 2/20 0.40
▸ ALDH1A1 P00352 2/20 0.40
▸ NFKB1 P19838 1/20 0.40
▸ NFKB2 Q00653 1/20 0.40
▸ RELA Q04206 1/20 0.40
▸ TP53 P04637 1/20 0.40
▸ HPGD P15428 1/20 0.40
▸ ALOX15 P16050 1/20 0.40
▸ HSD17B10 Q99714 1/20 0.40
▸ CYP19A1 P11511 2/20 0.40
▸ LMNA P02545 1/20 0.39
▸ PLA2G1B P04054 1/20 0.39
▸ HTT P42858 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30425840 0.86 HDAC6 (0.54) HDAC6SRCHDAC1
SCHEMBL25215921 0.86 HDAC6 (0.54) HDAC6SRCHDAC1
SCHEMBL25351111 0.85 PTGES (0.43) HDAC6RAB9ANPC1KDM4EALDH1A1
SCHEMBL25222471 0.85 HDAC6 (0.52) HDAC6CDC7SRCRAB9ASMN1; SMN2
SCHEMBL24215835 0.83 HDAC6 (0.62) HDAC6RAB9ANPC1CYP19A1HDAC8
SCHEMBL24599266 0.82 HDAC6 (0.61) HDAC6RAB9ANPC1CYP19A1EPHB4
SCHEMBL24599276 0.82 HDAC6 (0.56) HDAC6RAB9ANPC1CYP19A1EPHB4
SCHEMBL25351431 0.81 HDAC6 (0.42) HDAC6
SCHEMBL25386563 0.81 HDAC6 (0.60) HDAC6RAB9ANPC1CYP19A1EPHB4
SCHEMBL22558008 0.81 HDAC6 (0.62) HDAC6RAB9ANPC1CYP19A1EPHB4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116157398-B Oxadiazole-based selective histone deacetylase 6 inhibitors 意大发马克股份公司 2025-03-11 — — CN claimed
EP-4192830-A1 2-(4-((5-(BENZO[B]THIOPHEN-3-YL)-1H-TETRAZOL-1-YL)METHYL)PHENYL)-5-(DIFLUOROMETHYL)-1,3,4-OXADIAZOLE DERIVATIVES AND SIMILAR COMPOUNDS AS SELECTIVE INHIBITORS OF HISTONE DEACETYLASE 6 (HDAC6) FOR USE IN TREATING E.G. PERIPHERAL NEUROPATHY Italfarmaco SpA (IT) 2023-06-14 — — EP claimed
CN-116157398-A 2- (4- ((5- (benzo [ b ] thiophen-3-yl) -1H-tetrazol-1-yl) methyl) phenyl) -5- (difluoromethyl) -1,3, 4-oxadiazole derivatives and similar compounds as selective inhibitors of histone deacetylase 6 (HDAC 6) for the treatment of, for example, peripheral neuropathy 意大发马克股份公司 2023-05-23 — — CN claimed
CN-116157398-B Oxadiazole-based selective histone deacetylase 6 inhibitors 意大发马克股份公司 2025-03-11 — — CN disclosed
US-12202823-B2 1,3,4-oxadiazole derivatives as histone deacetylase inhibitors QUIMATRYX, S.L. (ES) 2025-01-21 — — US disclosed
EP-3956324-B1 1,3,4-OXADIAZOLE DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS QUIMATRYX S L (ES) 2024-02-21 — — EP disclosed
EP-4192830-A1 2-(4-((5-(BENZO[B]THIOPHEN-3-YL)-1H-TETRAZOL-1-YL)METHYL)PHENYL)-5-(DIFLUOROMETHYL)-1,3,4-OXADIAZOLE DERIVATIVES AND SIMILAR COMPOUNDS AS SELECTIVE INHIBITORS OF HISTONE DEACETYLASE 6 (HDAC6) FOR USE IN TREATING E.G. PERIPHERAL NEUROPATHY Italfarmaco SpA (IT) 2023-06-14 — — EP disclosed
CN-116157398-A 2- (4- ((5- (benzo [ b ] thiophen-3-yl) -1H-tetrazol-1-yl) methyl) phenyl) -5- (difluoromethyl) -1,3, 4-oxadiazole derivatives and similar compounds as selective inhibitors of histone deacetylase 6 (HDAC 6) for the treatment of, for example, peripheral neuropathy 意大发马克股份公司 2023-05-23 — — CN disclosed
US-20220213084-A1 1,3,4-OXADIAZOLE DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS FUNDACIÓN KERTOR (ES) 2022-07-07 — — US disclosed
US-20220213084-A1 1,3,4-OXADIAZOLE DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS FUNDACIÓN KERTOR (ES) 2022-07-07 — — US disclosed
EP-3956324-A1 1,3,4-OXADIAZOLE DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS QUIMATRYX, S.L. (ES) 2022-02-23 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220213084-A1 1,3,4-OXADIAZOLE DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS HDAC6, HDAC1, HDAC3 HDAC6 1/4885CDC7 1053/4885SPHK2 2001/4885
US-12202823-B2 1,3,4-oxadiazole derivatives as histone deacetylase inhibitors HDAC6, HDAC1, HDAC3 HDAC6 1/4885CDC7 1053/4885SPHK2 2001/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback